Management and Board

Management

Tor Peters

Tor Peters, CEO Occlutech Group, has over 30 years’ experience in senior positions at various med-tech companies. After a BSc at the University of Lund, three years as a global product manager with BOC Ohmeda and an MBA at IMD in Switzerland, he worked as a global marketing manager for Novo Nordisk and as a European marketing manager for Scimed/Boston Scientific.

In 1996 he co-founded JOMED, an innovative European interventional cardiology company and achieved the largest global med-tech IPO in 2000. After 5 years the company had over 1,500 employees and a market capitalization exceeding EUR 2 billion. He joined Occlutech in 2005 and has been the Group’s CEO and board member since 2009. He is also a board member of several high-tech life science companies in the cardiac assist, piezotronic and dental implant sectors.

Sabine Bois

Sabine Bois, Co-CEO and CFO Occlutech Group, holds an MBA degree specializing in Entrepreneurship and Finance. She has over 10 years’ experience in the Biotech/Med-tech industry. She supported the foundation of three successful start-ups and co-founded a biotech company in 2007.

As Managing Director, she structured and led several rounds of fundraising, managed the Finance, Investor Relations, and Operations units, while also building up a worldwide sales and distribution network. After selling the company in 2013 she joined Occlutech in March 2014.

Patrick NJ Schnegelsberg

Patrick NJ Schnegelsberg, COO Occlutech Group, graduated from MIT and Harvard Medical School. Prior to joining Occlutech, Patrick held CEO positions at privately-held NOLabs AB (MedTech) and at US - Israeli listed GammaCan Ltd. (Oncology).

Patrick’s other relevant professional experiences include work on both the buy and sell-sides with Rodman & Renshaw LLC, Achelous Partners LLC, Mehta Partners LLC, as well as management consultant with Booz & Co.

Board

Christian Risch

Christian Risch, has been a partner of the BDS Consulting Group Zurich and Schaffhausen since 1986 and a managing partner since 2000. Previously he worked in various interim management positions in the machine-building and electrical industry.

He is a major shareholder and Chairman of Vetter AG, a Schaffhausen-based company operating in the engineering field and producing temperature controllers for injection moulding systems. He holds numerous other board positions including at the Schaffhauser Kantonalbank, Escatec Group Malaysia and other global companies.

Reto Garzetti

Reto Garzetti, received his MBA from the University of Zürich, Switzerland. Thereafter he was an executive assistant for Credit Suisse and founded the first international PE fund for CS.

He subsequently led various industrial restructurings in the early ‘90s. Since 1994 he has been an entrepreneur in the med-tech, pharmaceutical, precision machining and real estate sectors. Today, in these areas, he holds numerous board seats in listed and non-listed companies. He lives and works out of Zurich, Switzerland.

Toru Takamiya

Toru Takamiya, has an experienced healthcare industry career spanning over 25 years, mainly in the cardiovascular and cardiology fields. He started his carrier with Terumo Medical Corporation as an engineer where he worked in both Japan and the US.

He was an international marketing executive in the US and Southeast Asia for over 7 years. He currently works for Japan Lifeline Co. Ltd, as Vice President Cardiovascular Business Unit.

Mr Takamyia is currently a member of the board of directors at Japan Lifeline, a public Japanese company in the area of cardiology.

Tor Peters

Tor Peters, CEO Occlutech Group, has over 30 years’ experience in senior positions at various med-tech companies. After a BSc at the University of Lund, three years as a global product manager with BOC Ohmeda and an MBA at IMD in Switzerland, he worked as a global marketing manager for Novo Nordisk and as a European marketing manager for Scimed/Boston Scientific.

In 1996 he co-founded JOMED, an innovative European interventional cardiology company and achieved the largest global med-tech IPO in 2000. After 5 years the company had over 1,500 employees and a market capitalization exceeding EUR 2 billion. He joined Occlutech in 2005 and has been the Group’s CEO and board member since 2009. He is also a board member of several high-tech life science companies in the cardiac assist, piezotronic and dental implant sectors.